Exploring New Settings for Tagraxofusp: CMML and Myelofibrosis

Tagraxofusp, a CD123-directed cytotoxin FDA approved for adults and children with blastic plasmacytoid dendritic cell neoplasm, demonstrates efficacy and safety in patients with relapsed/refractory myelofibrosis, according to data presented at the 2019 American Society of Clinical Oncology Annual Meeting.

ASH Clinical News